JP2022512595A5 - - Google Patents

Info

Publication number
JP2022512595A5
JP2022512595A5 JP2021518493A JP2021518493A JP2022512595A5 JP 2022512595 A5 JP2022512595 A5 JP 2022512595A5 JP 2021518493 A JP2021518493 A JP 2021518493A JP 2021518493 A JP2021518493 A JP 2021518493A JP 2022512595 A5 JP2022512595 A5 JP 2022512595A5
Authority
JP
Japan
Prior art keywords
cancer
mva
administered
taa
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021518493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512595A (ja
JP7555334B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/076947 external-priority patent/WO2020070303A1/en
Publication of JP2022512595A publication Critical patent/JP2022512595A/ja
Publication of JP2022512595A5 publication Critical patent/JP2022512595A5/ja
Application granted granted Critical
Publication of JP7555334B2 publication Critical patent/JP7555334B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021518493A 2018-10-05 2019-10-04 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 Active JP7555334B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18199002.9 2018-10-05
EP18199002 2018-10-05
PCT/EP2019/076947 WO2020070303A1 (en) 2018-10-05 2019-10-04 Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist

Publications (3)

Publication Number Publication Date
JP2022512595A JP2022512595A (ja) 2022-02-07
JP2022512595A5 true JP2022512595A5 (https=) 2022-09-26
JP7555334B2 JP7555334B2 (ja) 2024-09-24

Family

ID=63998486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518493A Active JP7555334B2 (ja) 2018-10-05 2019-10-04 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法

Country Status (7)

Country Link
US (1) US20240269254A1 (https=)
EP (1) EP3860641A1 (https=)
JP (1) JP7555334B2 (https=)
AU (1) AU2019354101B2 (https=)
CA (1) CA3113818A1 (https=)
IL (1) IL281988B2 (https=)
WO (1) WO2020070303A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
SK4272001A3 (en) 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
DE60235041D1 (de) 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
NZ592082A (en) 2008-11-27 2013-03-28 Bavarian Nordic As Promoters for recombinant viral expression
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
EP2482849B1 (en) 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
EP3147297B1 (en) 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
EP2800762B1 (en) 2012-01-03 2018-01-03 The United States of America, as represented by the Secretary, Department of Health and Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
WO2013189611A1 (en) 2012-06-22 2013-12-27 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
WO2014037124A1 (en) 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
EP2908851A1 (en) 2012-10-19 2015-08-26 Bavarian Nordic Inc. Methods and compositions for the treatment of cancer
EP2912183B1 (en) 2012-10-28 2020-05-06 Bavarian Nordic A/S Pr13.5 promoter for robust t-cell and antibody responses
AU2014347004B2 (en) * 2013-11-05 2019-08-08 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
KR20150135148A (ko) 2014-05-23 2015-12-02 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
EP4523756A3 (en) 2015-02-13 2025-05-28 Transgene Immunotherapeutic vaccine and antibody combination therapy
ES2901468T3 (es) 2015-07-31 2022-03-22 Bavarian Nordic As Promotores para mejorar la expresión en poxvirus

Similar Documents

Publication Publication Date Title
JP2022512595A5 (https=)
Liu et al. Turning cold tumors into hot tumors by improving T-cell infiltration
P Torres et al. Mucin-based targeted pancreatic cancer therapy
Chakraborty et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing
US11723964B2 (en) Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA
Kudo-Saito et al. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses
Harrop et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses
US20200085891A1 (en) Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
JP2021500932A5 (https=)
Lubaroff Prostate cancer vaccines in clinical trials
KR20170003556A (ko) 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법
Drerup et al. Immunotherapy for ovarian cancer
JP2017515841A5 (https=)
US11617767B2 (en) Armed dual CAR-T compositions and methods for cancer immunotherapy
JP2022507744A5 (https=)
Chang et al. Vaccinating against cancer: getting to prime time
JP2023503857A5 (https=)
Zhang et al. Management of castrate resistant prostate cancer—recent advances and optimal sequence of treatments
Che et al. The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise
Triulzi et al. Antibody-dependent natural killer cell–mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors
Izzi et al. Poxvirus-based vaccines for cancer immunotherapy: New insights from combined cytokines/co-stimulatory molecules delivery and “uncommon” strains
US20230287067A1 (en) Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs)
Gulley et al. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver
Skog Glioma-specific antigens for immune tumor therapy
Kudo-Saito et al. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity